Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies

Affiliations

• 1 Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• 2 Yale University and Yale Cancer Center, New Haven, CT, USA.
• 3 Moffitt Cancer Center, Tampa, FL, USA.
• 4 Florida Cancer Specialists, Sarasota, FL, USA.
• 5 Norton Cancer Institute, Louisville, KY, USA.
• 6 Florida Cancer Specialists, Lake Mary, FL, USA.
• 7 University of Iowa, Iowa City, IA, USA.
• 8 MD Anderson Cancer Center, Houston, TX, USA.
• 9 Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
• 10 Montefiore Einstein Comprehensive Cancer, Bronx, NY, USA.
• 11 Prelude Therapeutics, Wilmington, DE, USA.
• 12 Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].
• 13 Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].
• 14 Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].
• # Contributed equally.